Cookies on this site

Phase 1 of the INTERCEPT-Lynch trial, which is funded by Moderna, sponsored by the University of Oxford and run by the University's Oncology Clinical Trials Office with support from Oxford Cancer, has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.

Doctor using a laptop

The trial forms part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention. Led by Professor David Church, Cancer Research UK Senior Cancer Research Fellow in the University of Oxford’s Centre for Human Genetics in the Nuffield Department of Medicine, it will test ‘mRNA-4194’, an investigational mRNA-based vaccine developed by Moderna, which is designed to help prevent cancer in people with Lynch syndrome (LS).

LS is an inherited condition that affects around one in 300 people worldwide, which causes lifetime cancer risk of up to 80%. People with the condition face elevated risks of several cancer types, including colorectal, endometrial, ovarian, stomach, pancreatic and prostate cancers.

mRNA-4194 is designed to leverage mRNA technology to train the immune system to recognise and eliminate pre-cancerous cells in LS before cancer develops. The trial will administer the vaccine to participants with LS to assess safety, characterise immune response and determine the optimal dose for further testing. It is anticipated that the first participant will receive the vaccine in Oxford this summer. A second phase of the trial, expected to begin in 2027, will expand recruitment to additional centres across the UK.

“People with Lynch syndrome live with a very high risk of developing cancer, often at a younger age than the general population. The INTERCEPT-Lynch trial represents a meaningful step in our efforts to prevent Lynch syndrome-associated cancers before they develop,” said Professor David Church. “By using mRNA vaccine technology to train the immune system to recognise early cancer changes, or what we call ‘pre-cancer,’ we hope to reduce cancer risk and ultimately improve the lives of people with this inherited condition.” 

Read the full story on the Oxford Cancer website.

 

 

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

Five European Research Council (ERC) Synergy Grants awarded to Oxford researchers for ambitious new collaborations

Five Oxford University academics are to co-lead ambitious new research projects backed by European Research Council (ERC) Synergy Grants, part of the EU’s Horizon Europe research and innovation programme. Synergy Grants support groups of two to four outstanding researchers who combine complementary expertise and resources to tackle ambitious scientific challenges that could not be addressed by individual teams alone.

Professor Ole Jensen (Department of Experimental Psychology) and colleagues received €13.6 million to discover when the brain is ready for language and social understanding

The team will use new wearable brain sensors to track cognitive development from before birth to eight years of age.

New 'molecular glue' helps break down antibiotic resistance enzymes in E. coli

Oxford University scientists have discovered a new approach to tackle antimicrobial resistance (AMR), using 'molecular glues' to encourage bacteria to destroy their own resistance-causing enzymes. The study has been published in Angewandte Chemie International Edition.

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at the Nuffield Department of Population Health.

The Nuffield Department of Women's & Reproductive Health has published its Biennial Report 2024–26

The Biennial Report 2024–26 highlights two years of research excellence, innovation, collaboration and growth.